JP2024507937A5 - - Google Patents

Info

Publication number
JP2024507937A5
JP2024507937A5 JP2023551762A JP2023551762A JP2024507937A5 JP 2024507937 A5 JP2024507937 A5 JP 2024507937A5 JP 2023551762 A JP2023551762 A JP 2023551762A JP 2023551762 A JP2023551762 A JP 2023551762A JP 2024507937 A5 JP2024507937 A5 JP 2024507937A5
Authority
JP
Japan
Prior art keywords
sequence
antibody according
multispecific antibody
antigen
binding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/054993 external-priority patent/WO2022180271A1/en
Publication of JP2024507937A publication Critical patent/JP2024507937A/ja
Publication of JP2024507937A5 publication Critical patent/JP2024507937A5/ja
Pending legal-status Critical Current

Links

JP2023551762A 2021-02-26 2022-02-28 Cd123及びガンマデルタt細胞受容体に結合する抗体 Pending JP2024507937A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21159698 2021-02-26
EP21159698.6 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US63/166,339 2021-03-26
US202163274709P 2021-11-02 2021-11-02
US63/274,709 2021-11-02
EP21211114 2021-11-29
EP21211114.0 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (2)

Publication Number Publication Date
JP2024507937A JP2024507937A (ja) 2024-02-21
JP2024507937A5 true JP2024507937A5 (https=) 2025-02-27

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551762A Pending JP2024507937A (ja) 2021-02-26 2022-02-28 Cd123及びガンマデルタt細胞受容体に結合する抗体

Country Status (9)

Country Link
US (1) US20240141071A1 (https=)
EP (1) EP4298125A1 (https=)
JP (1) JP2024507937A (https=)
KR (1) KR20230169950A (https=)
AU (1) AU2022225091A1 (https=)
BR (1) BR112023017099A2 (https=)
CA (1) CA3209454A1 (https=)
MX (1) MX2023009950A (https=)
WO (1) WO2022180271A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2025012118A2 (en) * 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
DK3129404T3 (da) 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
KR20260046525A (ko) * 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
JP2022532868A (ja) * 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Cd123結合性ポリペプチド及びその使用
MA55903A (fr) 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t

Similar Documents

Publication Publication Date Title
JP2024507937A5 (https=)
JP2021511807A5 (https=)
JP2020010699A5 (https=)
JP2024501403A5 (https=)
JP2021508469A5 (https=)
JP2021524267A5 (https=)
HRP20191584T1 (hr) Anti-cd79b protutijela i načini uporabe
JP2021510521A5 (https=)
HRP20191174T1 (hr) Bispecifične molekule vezane na antigen koji aktivira t stanicu
JP2021511064A5 (https=)
JP2019533441A5 (https=)
JP2022519082A5 (https=)
JP2020504723A5 (https=)
JP2020511947A5 (https=)
JP2018522541A5 (https=)
RU2019134338A (ru) Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP2019502712A5 (https=)
RU2018143439A (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент
JP2018519263A5 (https=)
JP2023532129A5 (https=)
CA3091140A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2017504314A5 (https=)
JP2017534646A5 (https=)
JP2020502233A5 (https=)